Summit Therapeutics (SMMT) Receivables - Net (2017 - 2022)

Summit Therapeutics (SMMT) has reported Receivables - Net for 6 consecutive years, with $349000.0 the latest figure, recorded in Q4 2022.

• Quarterly Receivables - Net fell 76.16% year-over-year to $349000.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $349000.0 (down 76.16% YoY) and the FY2022 annual result came in at $349000.0, down 76.16% from the prior year.
• Receivables - Net improved to $349000.0 in Q4 2022 per SMMT's latest filing, from $140000.0 in the prior quarter.
• Over the last five years, Receivables - Net for SMMT reached as high as $17.3 million in Q1 2019 and fell as low as $140000.0 in Q3 2022.
• A 5-year average of $5.7 million and a median of $1.9 million in 2021 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2018 — Receivables - Net jumped 1072.16% — and 2020, when it tumbled 96.83%.
• Year by year, Receivables - Net stood at $14.9 million in 2018, then slumped by 30.16% to $10.4 million in 2019, then plunged by 96.83% to $331000.0 in 2020, then surged by 342.3% to $1.5 million in 2021, then sank by 76.16% to $349000.0 in 2022.
• According to Business Quant data, Receivables - Net over the past three periods registered $349000.0, $140000.0, and $238000.0 for Q4 2022, Q3 2022, and Q2 2022 respectively.